Age-related macular degeneration: the optometrist's role in detection and management
18 November 2014
Volume 15, Issue 4
The role of optometrist in the detection and management of AMD in the UK
and Australia.
Introduction
Age-related macular degeneration (AMD) is a leading cause of global blindness and vision impairment (Pascolini and Mariotti 2012). In the UK nearly 60% of cases of registered sight impairment and severe sight impairment are attributable to AMD (Bunce et al. 2010). Similarly, in Australia, the synthesis of data from the Melbourne Visual Impairment Project and the Blue Mountains Eye Study indicates that AMD is responsible for almost half of all cases of ‘blindness’ (Taylor et al. 2005). Around 600 000 people in the UK have AMD, a figure that is expected to rise to around 750 000 by 2020 (Minassian et al. 2011).
Sign in to view the article
Not a member? Start enjoying the benefits of College membership today. Take a look at what the College can offer you and view our membership categories and rates.
Related further reading
Our Clinical Adviser comments on the story in the BBC about the woman who had gene therapy to try to halt the progression of age-related macular degeneration (AMD).
Our Clinical Adviser offers his advice, following an article by The Express on the best supplements for eyes.
Chris Steele FCOptom, new Clinical Editor of Acuity, on change as a positive factor